GlassScriptPhysician profile
Kareem Ibrahim
NPI 1760771653
$15,284.79
in general payments reported to CMS, 2019-2025
22 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $3,383 · 2021: $3,750 · 2022: $2,720 · 2023: $2,115 · 2024: $866 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,028.34 | 2019-2025 | Da Vinci Surgical System |
| Merit Medical Systems INC | $782.61 | 2022 | |
| Davol INC. | $498.55 | 2022-2024 | Progel Applicator Spray Tips |
| Medtronic, INC. | $365.55 | 2023-2025 | Signia |
| Medela LLC | $316.50 | 2024 | Art. 101030215 Thopaz+ Chest Drainage, Dominant Flex |
| Abiomed | $146.76 | 2019 | |
| Celgene Corporation | $138.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $136.11 | 2019-2023 | Imfinzi |
| Atricure, INC. | $129.87 | 2021-2023 | |
| Stryker Corporation | $126.68 | 2024 | 1788 |
| Galvanize Therapeutics, INC | $102.79 | 2023 | Aliya System |
| Ethicon US, LLC | $93.00 | 2019-2021 | |
| Baxter Healthcare | $90.89 | 2020-2023 | Tisseel |
| E.R. Squibb & Sons, L.L.C. | $82.52 | 2023 | Opdivo |
| Becton, Dickinson and Company | $70.75 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bolton Medical INC | $58.50 | 2022 | |
| Lilly USA, LLC | $29.73 | 2019-2020 | |
| Janssen Biotech, INC. | $24.31 | 2024 | Rybrevant |
| Genentech USA, INC. | $20.95 | 2024 | Tecentriq, Tecentriq Hybreza |
| Foundation Medicine, INC. | $15.73 | 2020 | |
| Mirati Therapeutics, INC. | $13.34 | 2023 | Krazati |
| Integra Lifesciences Corporation | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kareem Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.